 SAN DIEGO, California, Aug. 06, 2020 GLOBE NEWSWIRE -- La Jolla Pharmaceutical Company Nasdaq: LJPC, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2020 and highlighted recent corporate progress.Recent Corporate Progress Acquisition of Tetraphase Pharmaceuticals, Inc.: On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on commercializing its novel tetracycline, XERAVATM eravacycline, to treat serious and life-threatening infections, for 43 million in upfront cash plus potential future cash payments of up to 16 million. For the three and six months ended June 30, 2020, U.S. net sales of XERAVA, which was launched in October 2018, were 1.5 million and 3.2 million, up 88 and 191, respectively, from the same periods in 2019. Complete financial results of Tetraphase for the six months ended June 30, 2020 will be included in an amended Form 8-K to be filed by La Jolla on or before October 13, 2020. Financial results for periods ending September 30, 2020 and beyond will include Tetraphases financial results subsequent to the acquisition closing date of July 28, 2020. Appointment of Larry Edwards as President and Chief Executive Officer: Effective July 28, 2020, La Jollas Board of Directors appointed Larry Edwards as President and Chief Executive Officer of La Jolla.With two, FDA-approved, innovative therapies for life-threatening diseases, La Jolla is well-positioned to help patients in need, said Larry Edwards, President and Chief Executive Officer of La Jolla. By leveraging the stronger platform that the combined company will provide, we look forward to increasing patient access to these important medicines.Financial ResultsFor the three and six months ended June 30, 2020, U.S. net sales of GIAPREZA were 5.8 million and 13.4 million, up 2 and 33, respectively, from the same periods in 2019.La Jollas net loss for the three and six months ended June 30, 2020 was 15.6 million and 24.2 million, or 0.57 and 0.89 per share, respectively, compared to 30.4 million and 62.1 million, or 1.12 per share and 2.29 per share, respectively, for the same periods in 2019.As of June 30, 2020, La Jolla had 71.4 million of cash and short-term investments, compared to 87.8 million as of December 31, 2019. Net cash used in operating activities for the three and six months ended June 30, 2020 was 8.4 million and 20.6 million, respectively, down 49 and 58, respectively, from the same periods in 2019.About GIAPREZAGIAPREZATM angiotensin II for injection is approved by the U.S. Food and Drug Administration FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission EC for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the bodys endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at The European Summary of Product Characteristics is available on the EMA website: GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.GIAPREZA Important Safety InformationContraindicationsNone.Warnings and PrecautionsThere is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism VTE prophylaxis.Adverse ReactionsThe most common adverse reactions that were reported in greater than 10 of GIAPREZA-treated patients were thromboembolic events.Drug InteractionsAngiotensin converting enzyme ACE inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers ARBs may reduce response to GIAPREZA.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union.About XERAVAXERAVATM eravacycline for injection is a novel fluorocycline of the tetracycline class of antibacterials that is approved by the U.S. Food and Drug Administration FDA for the treatment of complicated intraabdominal infections cIAI in patients 18 years of age and older. XERAVA is approved by the European Commission EC for the treatment of cIAI in adults. Prescribing information for XERAVA is available at XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla.XERAVA Important Safety InformationXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.XERAVA is not indicated for the treatment of complicated urinary tract infections.To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity anaphylactic reactions have been reported with XERAVA.The use of XERAVA during tooth development last half of pregnancy, infancy and childhood to the age of eight years may cause permanent discoloration of the teeth yellow-gray-brown and enamel hypoplasia.The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.Clostridium difficile associated diarrhea CDAD has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.The most common adverse reactions observed in clinical trials incidence 3 were infusion site reactions, nausea and vomiting.XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States.About La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZATM angiotensin II is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVATM eravacycline is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit StatementsThis press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on managements expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZATM angiotensin II and XERAVATM eravacycline sales; whether La Jolla will realize the benefits from the acquisition of Tetraphase Pharmaceuticals, Inc.; regulatory actions relating to La Jollas products by the U.S. FDA, European Commission andor other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. 